Abstract library

9 results for "Jouret-Mourin".
#90 The prognostic value of FDG-PET scan in neuroendocrine tumors: a retrospective analysis of 46 patients treated in one center
Introduction: Neuroendocrine tumors (NETs) are rare and generally indolent. For diagnostic purposes, the sensitivity of FDG-PET scan is known to be low in this setting, though when positive, its prognostic value is not well-defined in NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Ivan Borbath
#126 Assessment of the proliferation marker Ki-67 by endoscopic ultrasound guided-Fine Needle Aspiration (EUS-FNA) in pancreatic endocrine tumors: A comparative analysis with histology of the surgical specimen
Introduction: Assessment of the proliferative index by Ki-67 immuno-labelling is an important prognostic parameter for the biologic behavior of digestive neuroendocrine tumors, usually established on the histological specimen obtained after surgery or macro-biopsy. However, small pancreatic endocrine tumors (PET) are more and more often recognized by CT/MRI and diagnosed by EUS. The value of Ki-67 labelling index (Ki-67-LI) on fine needle aspiration (FNA) is not well-established in this setting, although regularly assessed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Ivan Borbath
#1609 Prognostic Relevance of Pancreatic Neuroendocrine Tumors Grading on EUS-FNA
Introduction: Since WHO 2010, resected pNETs are graded as G1, G2 or G3 using the Ki67-LI. EUS-FNA is often used for diagnosis but few studies have assessed its value for grading.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Prof. Dr. Ivan Borbath
Keywords: EUS-FNA, KI67, pNET, OS
#963 From E.L.I.O.S. (Educational Learning Investigational Observational Study) an Initial Update on Neuroendocrine Tumors (NETs) in the Southern Italy
Introduction: Elios is an Educational Learning Investigational Observational Study.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Salvatore Tafuto
#1000 E.L.I.O.S. (Educational Learning Investigational Observational Study): An Initial Update on Neuroendocrine Tumors (NETs) in the Southern Italy
Introduction: Elios is an Educational Learning Investigational Observational Study.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Salvatore Tafuto
#1131 M-TORC1 Complex Is Significantly Over-Activated in SDHx-Mutated Paragangliomas
Introduction: The activation patterns of mTOR pathway in sporadic and hereditary pheochromocytomas (PCC) and paragangliomas (PGL) are poorly recognized.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: MD, PhD Marco Volante
Keywords: PCC, PGL, mTOR, SDHx
#1360 Development and Validation of Nomogram in Predicting Individualized Postoperative Survival for Nonfunctional Pancreatic Neuroendocrine Tumors: A Multicenter Retrospective Study
Introduction: NA
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Xu Han
Authors: Han X, Ma H, Feng J, Xu X, ...
#1736 Slit2-Robo1 Signaling Activates Ras to Suppress Metastasis and Is Associated with Time-To-Progression in Pancreatic Neuroendocrine Tumors
Introduction: Transcriptom analysis revealed that mRNA signatures of distinct metastatic phenotypes in pancreatic NETs (pNETs) exhibit differences in components of the Slit-Robo pathway.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: PD Dr. med. Christian Fischer
#2107 Carboplatin-Etoposide Chemotherapy (CB-ET) for Patients Diagnosed with Advanced Extra-Pulmonary (EP) Poorly Differentiated (PD) Neuroendocrine Carcinoma (NEC): Findings from a European Neuroendocrine Tumour Society Centre of Excellence
Introduction: Carboplatin-Etoposide is a first-line option for patients (pts) with advanced EP-PD-NEC. Data from randomised trials are lacking
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Melissa Frizziero